KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Debt to Equity (2016 - 2025)

Sarepta Therapeutics has reported Debt to Equity over the past 16 years, most recently at $0.73 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 2.36% year-over-year to $0.73; the TTM value through Dec 2025 reached $0.73, down 2.36%, while the annual FY2025 figure was $0.73, 2.36% down from the prior year.
  • Debt to Equity for Q4 2025 was $0.73 at Sarepta Therapeutics, down from $0.81 in the prior quarter.
  • Over five years, Debt to Equity peaked at $4.01 in Q4 2022 and troughed at $0.73 in Q4 2025.
  • A 5-year average of $1.61 and a median of $1.36 in 2023 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: soared 239.41% in 2022 and later tumbled 64.09% in 2023.
  • Year by year, Debt to Equity stood at $1.18 in 2021, then soared by 239.41% to $4.01 in 2022, then tumbled by 64.09% to $1.44 in 2023, then crashed by 48.33% to $0.74 in 2024, then decreased by 2.36% to $0.73 in 2025.
  • Business Quant data shows Debt to Equity for SRPT at $0.73 in Q4 2025, $0.81 in Q3 2025, and $0.84 in Q2 2025.